

An organoids and spheroids screening platform for therapeutic discoveries in cancer research



le propulseur régional des recherches et innovations anticancers

3D-Hub is a dual site platform based in Nice & Marseille.



- Generating 3D biological structures for cancer research devoted to academic, clinical and private research
- Analyzing tissue homeostasis to better understand developmental programs of cancer
- Mimicking tumoral initiation and progression to identify new molecular targets to block tumor expansion

IBiSA.

- Decoding the functional properties of the tissue of origin, including the genetic and the cellular heterogeneity for personalized medicine
- Training for 3D organoids and spheroids tissues cultures, participating in national and international consortiums for organoids and spheroids use in oncology, lectures and courses for students

Initiated by the Canceropôle Provence-Alpes-Côte d'Azur in 2019, 3D-Hub acquired the IBiSA label in 2021.



Scientific Heads:

Géraldine GUASCH organoide.3d-hub-o@inserm.fr

Cédric GAGGIOLI cedric.gaggioli@univ-cotedazur.fr




3D-Hub coordinator for Canceropôle Sud:

Laure VERRIER laure.verrier@univ-amu.fr



Uni-and multi-Cellular Spheroids Platform for Cancer Research

- Anti-cancer screening on spheroids and tumoroids
- Development of synthetic tumors in vitro
- Drug tests for personalized medicine
- Training, lectures and courses





Organoids Platform for Cancer Research

- Organoids cultures from normal and tumoral tissues
- Organoids genetic modifications
- Organoids chemical sensitivity
- Training, lectures and courses



CRCM






Géraldine GUASCH CRCM, Inserm U1068 MARSEILLE



🌐 Inserm

Growing National Network for 3D Tissue Cultures





3D-Hub is working in close collaboration with the tumoroid platforms of **Caen ORGAPRED** and **Lille OrgaRES** to accelerate the development and the exchange of tumoroid models and know-how. This coordination is performed in the context of the research cluster (GDR) "Organoïdes" labeled in 2021 by the **CNRS**, and with the help of the **Canceropôles Sud and Nord-Ouest.** We aim at budding a robust network that will allow the establishment of multiple links between our platforms, leading to efficient collaborations.

